Biocurious: The cannabis stocks that stand out in a field of weeds
Regulators have lax telehealth prescribers in their sights
Althea Group has sold its medical pot arm in favour of THC-infused beverages
Having sprouted in a field of hope and hype eleven years ago, the ASX medicinal cannabis sector has wilted in the face of unrealistic expectations and misguided strategies.
Demand isn't the problem: patients have embraced medical weed zealously since it was legalised a decade ago.
Globally, most western countries have sanctioned both medical usage and many have condoned recreational indulgence (including most US states).
Because there's only two approved cannabis treatments, local dispensing is largely carried out via an authorised prescriber scheme.
In the six months to December 2024, these docs wrote 377,840 prescriptions. Of these, 230,091 were for products with a THC content of more than 98%.
Patients aren't mucking around.
What's not to like?
The answer is rampant oversupply of the green stuff coupled with the rise of telehealth clinics, some of which are being criticised for alleged 'tick and flick' dispensing practices.
Echoing Australian Medical Association concerns, Little Green Pharma (ASX:LGP) CEO Paul Long refers to 'poor actors' in the local market.
'Reports constantly refer to a handful of doctors, often junior doctors that are either being coerced, or paid exorbitant money to write a huge volume of THC scripts,' he says.
'I agree it is an issue and calling it out for the long-term growth of our industry is important."
He adds hundreds of thousands have tried medical cannabis when nothing has worked, with great success.
Reflecting the 'commoditised' market, Althea Group (ASX:AGH) in May sold its local medical cannabis business, Tasmanian Botanics Pty Ltd for a knock-down $1 million.
'The market has become irrational,' says Althea CEO Joshua Fegan.
'It's very saturated, with product from places like Canada, South Africa and Colombia'.
He says most of the consumption is by way of dried flower, which implies folk might be smoking the devil's lettuce for jollies rather than using it medicinally.
We'll delve further into Althea's new direction below.
The dope on how to get it right
While most suppliers have withered, a handful prosper via differentiated strategies and perhaps a bit of luck. They are producing meaningful revenues and – in some cases - profits.
The Perth-based Little Green Pharma derives 80% of its revenue from the local market, but its greater fortunes align to the rapidly evolving European market.
Germany is in the throes of partial legalisation.
In France, the company supplies a pilot program that's a precursor to legalisation.
Little Green's owns a production facility in Denmark – Europe's biggest – purchased from Canada's Canopy Growth for a knock-down $20 million three years ago.
Two hours from the German border, the facility provides a streamlined route to the biggest Continental markets.
'It's very unlikely a site like this will be built again in the foreseeable future,' Little Green CEO Paul Long says.
Meanwhile, the company's Busselton facility becomes a 'craft' producer of a small amount of slowly cured, hand trimmed, genetically superior stuff.
Naturally, this attracts a better margin.
In the year to March 2025 Little Green grew its revenue by 43%, to a record $36.8 million 'against a backdrop of significant regulatory change and intense competition'.
European revenues doubled.
Adjusted for non-cash items, Little Green managed underlying earnings of $2.9 million compared with a previous $1.6 million loss.
From gummies to suppositories
Bioxyne (ASX:BXN) has a modest $64 million market cap, but that's big enough to confer 'sector leader' status.
Bioxyne's engine room is Breathe Life Sciences (BLS), acquired via scrip in 2023.
BLS makes and distributes medical cannabis and other consumer health products, either under its own brands or third-party labels.
(locally, Bioxyne is also the only licensed maker of MDMA and psilocybin for authorised prescribers and pyschedelic clinical trials).
In 2019 the company launched in the UK and Japan via its well-known Dr Watson brand, covering everything from gummies, to vapes to suppositories.
BLS too has entered the German market with a deal to supply a minimum 1.6 tonnes of cannabis flower and finished product to two clients.
The company expects the agreement will reap a minimum of $5.6 million of revenue in the 2025-26 year.
Ja, das ist gut!
Bioxyne CEO Sam Watson expects German demand to rapidly overtake the $1 billion a year Australian market.
On June 12 the company upgraded full-revenue expectations from $25 million to $28 million, a lofty step up from the previous year's $9.65 million.
The Ebay of medicinal dope
Formerly known as Cronos Australia, Vitura Health (ASX:VIT) doesn't produce any of its own material, but operates a marketplace that sells hundreds of flowers and oils from third party suppliers.
Vitura also has expanded into prescription nicotine vapes.
The company has built a network of physical and online prescribers, mainly via acquisition.
Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and the clinic chain Candor Medical.
In May, Vitura's 50% joint venture Flora acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'.
Established in 2020, the chain claims to have serviced more than more than 5000 patients.
Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics.
In a March quarter update, Vitura said full-year revenue was unlikely to meet the targeted 10% improvement. But the June quarter implies a yearly run rate of $138 million, up 11%.
Management also expects a 20% improvement on last year's normalised underlying earnings of $8.4 million.
Putting the pep into soft drinks
Coming back to Althea, the company's new schtick is entering the North American market for THC-infused beverages.
(THC is the psychoactive component of cannabis).
Yep, these bevvies are legal in Canada and the US and are sold in bottle shops alongside alcohol.
Althea's foray is by way of its subsidiary Peak.
Althea's Fegan says when Peak started producing in 2021, only 4% of cannabis consumers had tried these drinks. Now, the number is more like one-quarter of them.
He says the drinks have a similar effect to a similar sized serve of alcohol, but without the hangover.
'It ticks a lot of boxes as a good consumer product,' he says.
Peak's competitive edge is its technique to produce the THC emulsion, without the 'planty' taste of dope.
Peak's offerings include seltzers, sodas and mocktails – but it's not yet putting the 'pep' into Pepsi.
Peak Canada has just launched its own brand Snap Back, a heady mix of THC and rosin (pine resin).
By December Althea expects to have four or five US production sites, as close to distributors as possible.
'These big alcohol companies are looking closely at this space and our job is to develop drinks for those type of companies and produce them at scale," Fegan says.
In the December half, Althea derived $8.2 million of revenue in Canada and the company expects this to grow during the summer months.
Given the sale of its Australian business, Althea in May withdrew its full-year guidance of revenue between $26-33 million and underlying earnings of $800,000 to $1.1 million.
Althea lost $2.6 million in the March quarter. But Fegan says the company should be cash flow positive without the drag of the divested Australian business.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Perth Now
26 minutes ago
- Perth Now
Australian shares fall as volatility tipped to continue
The Australian bourse has moved lower despite tech industries spurring the US market to modest overnight gains. Near noon on Friday the benchmark S&P/ASX200 index was down 44.9 points, or 0.52 per cent, to 8,665.5, while the broader All Ordinaries had dipped by 44.5 points, or 0.5 per cent, to 8,934.5. Overseas, the US market lifted after Google's parent company Alphabet spurred the technology sector, securing a $1.5 billion deal with software firm ServiceNow. Tesla shares fell 8.2 per cent after its profit report disappointed, while US President Donald Trump denied on social media that he was seeking to destroy Elon Musk's companies. In Australia, nine of the ASX's 11 sectors were down near midday, lifted only by energy climbing 1.17 per cent and with health care almost flat at 0.04 per cent. With a few hours of trading left, the ASX200 was on track to fall 1.1 per cent for the week after breaking records multiple times the previous week. Volatility in the local market looks set to persist as traders eye upcoming inflation data, and the local earnings season, Moomoo dealing manager Paco Chow said. "Macro swings and stock-specific shocks are driving sharp moves across the region," he said on Friday. "Heading into today's session, expect Asia to take its cues from Tesla's drama, US tech euphoria, and fresh energy headlines, such as China's mega dam plans." The big four banks continued losing ground with CBA dropping 1.12 per cent, NAB shedding 1.21 per cent, Westpac down 1.29 per cent and ANZ losing 0.92 per cent. For the week the financial sector was on pace to drop 4.2 per cent, which would be its worst week since a 4.6 per cent loss in early March. Miners also disappointed with BHP losing 1.71 per cent, Fortescue dropping 3.05 per cent and Rio Tinto subtracting 1.28 per cent. Goldminers slipped with the exception of producer Newmont, which rose 3.17 per cent after reporting a quarterly adjusted net income of more than $2.4 billion. Energy was in the green after Woodside rose 2.45 per cent and Santos edged 0.5 per cent higher. KMD Brands rose 6.52 per cent after Qantas executive Carla Webb-Sear was appointed the Kathmandu and Rip Curl parent company's chief financial officer. The Australian dollar was buying 65.83 US cents, from 66.16 US cents about 5pm on Thursday.

Sydney Morning Herald
an hour ago
- Sydney Morning Herald
The big money behind childcare operator at the heart of alleged sex abuse scandal
The childcare operator at the centre of the sector's alleged sexual abuse scandal, Affinity Education, lost money last year as it continued with an acquisition binge designed to give its rich-lister backers a lucrative exit. The for-profit childcare sector at large has come under intensifying pressure following allegations that Joshua Dale Brown had allegedly sexually abused children at several Victorian centres, but the Quadrant Private Equity-owned Affinity has also been dogged by other alleged incidents. Brown's case is still being investigated and remains before the courts. Queensland Police charged a 21-year-old male employee of an Affinity centre in Brisbane on July 10 over an offence alleging indecent treatment of a child. That came as the list of centres that Brown worked at continued to balloon, including additional centres owned by Affinity. Scrutiny of Affinity has been limited compared with the ASX-listed G8 Education – which has had hundreds of millions of dollars wiped from its market capitalisation after the charges against Brown were made public – despite Affinity owning 13 of the 23 centres where Brown worked. But financial statements lodged with the corporate regulator by the Brisbane-headquartered Affinity portray a company on an expansion binge since Quadrant bought it in 2021. Financial statements lodged with ASIC show that in the 2024 calendar year, Affinity posted an after-tax loss of more than $20 million, with huge debt bills playing a significant role, despite underinvestment in staff compared with the rest of the industry. Affinity's accounts for the financial year ending December 31, 2024, show it was saddled with $614 million worth of loans, just shy of the $650 million that Quadrant paid for Affinity in 2021 when the company borrowings totalled $325 million.

The Age
an hour ago
- The Age
The big money behind childcare operator at the heart of alleged sex abuse scandal
The childcare operator at the centre of the sector's alleged sexual abuse scandal, Affinity Education, lost money last year as it continued with an acquisition binge designed to give its rich-lister backers a lucrative exit. The for-profit childcare sector at large has come under intensifying pressure following allegations that Joshua Dale Brown had allegedly sexually abused children at several Victorian centres, but the Quadrant Private Equity-owned Affinity has also been dogged by other alleged incidents. Brown's case is still being investigated and remains before the courts. Queensland Police charged a 21-year-old male employee of an Affinity centre in Brisbane on July 10 over an offence alleging indecent treatment of a child. That came as the list of centres that Brown worked at continued to balloon, including additional centres owned by Affinity. Scrutiny of Affinity has been limited compared with the ASX-listed G8 Education – which has had hundreds of millions of dollars wiped from its market capitalisation after the charges against Brown were made public – despite Affinity owning 13 of the 23 centres where Brown worked. But financial statements lodged with the corporate regulator by the Brisbane-headquartered Affinity portray a company on an expansion binge since Quadrant bought it in 2021. Financial statements lodged with ASIC show that in the 2024 calendar year, Affinity posted an after-tax loss of more than $20 million, with huge debt bills playing a significant role, despite underinvestment in staff compared with the rest of the industry. Affinity's accounts for the financial year ending December 31, 2024, show it was saddled with $614 million worth of loans, just shy of the $650 million that Quadrant paid for Affinity in 2021 when the company borrowings totalled $325 million.